The first-in-human trial of glycocalyx-edited autologous MSCs shows that engineering bone homing via sLeX expression reduces fragility fractures and increases bone density in advanced osteoporosis patients, with five-plus years of safety data and no serious adverse events.
The Cox et al. Phase 1/2a trial in Brain (2026) demonstrates that autologous adipose-derived MSCs reduce brain immune cell density and improve depression, fatigue, and pain in chronic TBI patients.
From MSC secretome to exosome injections and next-gen PRP alternatives, here is what 2026 research says about regenerative hair loss treatments — and who they work best for.
Recent Phase 2a clinical trials demonstrate that mesenchymal stem cell therapy can slow brain atrophy by up to 62% and reduce neuroinflammation in mild Alzheimer's patients. Review of laromestrocel trial data, biomarker outcomes, and emerging treatment options.
A comprehensive 2026 review of mesenchymal stem cell therapy for systemic sclerosis (scleroderma), covering iPSC-derived MSCs, refrigerated cell delivery, blood vessel organoid models, and the MANUS clinical trial for digital ulcers.
A 2026 meta-analysis pools 236 patients across 5 trials, and a 114-patient Phase 2 RCT shows MSC therapy achieves EASI-75 in 24% of severe AD patients. Exosome hydrogel delivery and batch consistency data now address the scalability questions that held this field back.
Multiple 2026 clinical trials and reviews show mesenchymal stem cell therapy is safe and feasible for Parkinson's disease — but what do the actual data say about efficacy, dosing, and what comes next?
The first FDA-approved MSC therapy (Ryoncil) ended a 20-year drought for cell-based products in the US. New real-world data from 139 children and next-generation platforms are reshaping how clinicians treat steroid-refractory pediatric GvHD.
A 2025 meta-analysis of 52 studies, real-world Taiwan data, and Mayo Clinic intraarterial delivery results — what nephrologists need to know about MSCs and CKD.
A medical review of MSC-based and MSC-derived EV therapies for idiopathic pulmonary fibrosis, covering meta-analysis data, immune-cloaked cell engineering, nebulized exosome delivery, gut-lung axis mechanisms, and active clinical trials.
Russian 
English 
Chinese 
French